Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Past 24 hours
Any time
Past hour
Past 7 days
Past 30 days
Most recent
Best match
PharmiWeb
7h
Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease statusConfirmatory data to support US regulatory resubmission by year-end; if ...
GlobalData on MSN
8h
Lilly’s EBGLYSS shows improvement in Phase IIIb study for atopic dermatitis
The ADapt study assessed the efficacy and safety of EBGLYSS in individuals who had previously been treated with dupilumab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Ballot boxes set on fire
Interagency operation at jail
Organ donors opting out
Murder suspect manhunt
Jay Johnston sentenced
‘The Warriors' actor dies
Jamshid Sharmahd executed
Heat honor Dwyane Wade
Iran warns Israel
Egypt proposes Gaza truce
CA crab season delayed
Screenwriter Taylor dies
Nobel laureate hospitalized
Indonesia bans iPhone 16
N. Korean troops in Ukraine
Oil prices fall
Launches election trading
Announces stock offering
Synagogue attack memorial
Massachusetts brush fire
Quarter Pounders return
Rare dime fetches $500K+
Stephen Curry injured
Plans major layoffs
Philadelphia DA sues Musk
VA appeals voter purge
D-Day veteran dies at 99
Norway buys US missiles
CA electric motorcycle plan
On Ukraine's use of US arms
Reddick wins NASCAR race
Related topics
Eli Lilly
EBGLYSS
Hives
Feedback